Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report.

Collette, Fanny;Hamoir, Marc;Van Eeckhout, Pascal;D'Abadie, Philippe;Machiels, Jean-Pascal;et.al.
(2020) Clinical Case Reports — Vol. 8, n° 12, p. 3472-3478 (2020)

Files

CCR3-8-3472.pdf
  • Open Access
  • Adobe PDF
  • 819.49 KB
Download

Details

Authors
  • Collette, Fannyorcid-logoUCLouvain
    Author
  • Hamoir, MarcUCLouvain
    Author
  • Van Eeckhout, PascalUCLouvain
    Author
  • D'Abadie, PhilippeUCLouvain
    Author
  • Duprez, Thierryorcid-logoUCLouvain
    Author
  • Schmitz, SandraUCLouvain
    Author
  • Machiels, Jean-PascalUCLouvain
    Author
Show more
Abstract
Primary cutaneous apocrine adenocarcinoma (PCAC) is an extremely rare neoplasm involving the sweat glands. Due to a lack of cases, there is no consensus for the systemic treatment of locally advanced or metastatic PCAC. Anti-androgen therapy may have activity in inoperable or metastatic PCAC with high androgen receptor (AR) expression.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Collette, F., Hamoir, M., Van Eeckhout, P., D’Abadie, P., Duprez, T., Schmitz, S., & Machiels, J.-P. (2020). Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report. Clinical Case Reports, 8(12), 3472-3478. https://doi.org/10.1002/ccr3.3434 (Original work published 2020)